Xue R, et al. - Researchers compared carboplatin to cisplatin in terms of effectiveness for treating cervical cancer when used as part of weekly concurrent chemoradiotherapy (Car-RT vs Cis-RT). They analyzed data from relevant prospective and retrospective studies identified via a literature search, with primary endpoints being complete response rate, progression-free survival/disease-free survival, overall survival, reported as odds ratios and 95% confidence intervals. The meta-analysis included 12 studies consisting of 1,698 patients. Findings demonstrated that a poorer tumor response and a trend toward inferior survival was reported in cases treated with Car-RT vs Cis-RT. Still, carboplatin was considered as a suitable concurrent agent for patients with contraindications to cisplatin as it displayed encouraging efficacy and low toxicity.